The stable outlook reflects Moody's expectation that Daiichi Sankyo's revenue will grow from ADC drugs and that debt will be retired as they mature. Moody's also expects collaboration with AstraZeneca will provide earnings growth for Daiichi Sankyo, although their profit sharing arrangement will cause profit growth to lag revenue growth.